These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2528436)

  • 21. [The acetylator polymorphism in a Khmer population: clinical consequences].
    Bechtel YC; Bechtel PR; Lelouët H; Choisy H; Dy NR
    Therapie; 2001; 56(4):409-13. PubMed ID: 11677864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphic N-acetylation of a caffeine metabolite.
    Grant DM; Tang BK; Kalow W
    Clin Pharmacol Ther; 1983 Mar; 33(3):355-9. PubMed ID: 6825389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of association between slow acetylator status and spontaneous lupus erythematosus.
    Kumana CR; Chan MM; Wong KL; Wong RW; Kou M; Lauder IJ
    Clin Pharmacol Ther; 1990 Aug; 48(2):208-13. PubMed ID: 2379389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between in vivo acetylator phenotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human uroepithelial cells.
    Frederickson SM; Messing EM; Reznikoff CA; Swaminathan S
    Cancer Epidemiol Biomarkers Prev; 1994; 3(1):25-32. PubMed ID: 8118381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities.
    McQuilkin SH; Nierenberg DW; Bresnick E
    Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):139-46. PubMed ID: 7742721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HPLC method for rapid determination of acetylator phenotype by measuring urinary caffeine metabolites.
    Klebovich I; Arvela P; Pelkonen O
    J Pharm Biomed Anal; 1993 Oct; 11(10):1017-21. PubMed ID: 8305582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Determination of caffeine metabolite for the evaluation of N-acetyltransferase, CYP1A2 and xanthine oxidase activities].
    Lu JF; Yi T; Cao XM; Zhuo HT; Ling SS
    Yao Xue Xue Bao; 1997 Nov; 32(11):813-8. PubMed ID: 11596199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aminopyrine metabolism in man: the acetylation of aminoantipyrine cosegregates with acetylation of caffeine.
    Agúndez JA; Carrillo JA; Martínez C; Benítez J
    Ther Drug Monit; 1995 Feb; 17(1):1-5. PubMed ID: 7725368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acetylation phenotypes and biological variation in a French Caucasian population.
    Pontes ZB; Vincent-Viry M; Gueguen R; Galteau MM; Siest G
    Eur J Clin Chem Clin Biochem; 1993 Feb; 31(2):59-68. PubMed ID: 8467011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways.
    Carrillo JA; Benítez J
    Clin Pharmacol Ther; 1994 Mar; 55(3):293-304. PubMed ID: 8143395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salivary sialic acid, protein, salivary flow rate, pH, buffering capacity and caries indices in subjects with Down's syndrome.
    Yarat A; Akyüz S; Koç L; Erdem H; Emekli N
    J Dent; 1999 Feb; 27(2):115-8. PubMed ID: 10071468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between metabolic phenotype of N-acetylation and bladder cancer.
    Cui X; Guo R; Xu Z; Wang B; Li C
    Chin Med J (Engl); 2000 Apr; 113(4):303-5. PubMed ID: 11775223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validity of an ELISA for N-acetyltransferase-2 (NAT2) phenotyping.
    Wong P; Banerjee K; Massengill J; Nowell S; Lang N; Leyland-Jones B
    J Immunol Methods; 2001 May; 251(1-2):1-9. PubMed ID: 11292476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Caffeine acetylator phenotyping during maturation in infants.
    Pariente-Khayat A; Pons G; Rey E; Richard MO; D'Athis P; Moran C; Badoual J; Olive G
    Pediatr Res; 1991 May; 29(5):492-5. PubMed ID: 1896253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decline in cerebral glucose utilisation and cognitive function with aging in Down's syndrome.
    Schapiro MB; Haxby JV; Grady CL; Duara R; Schlageter NL; White B; Moore A; Sundaram M; Larson SM; Rapoport SI
    J Neurol Neurosurg Psychiatry; 1987 Jun; 50(6):766-74. PubMed ID: 2956363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A competitive enzyme linked immunosorbent assay for the determination of N-acetyltransferase (NAT2) phenotypes.
    Wong P; Leyland-Jones B; Wainer IW
    J Pharm Biomed Anal; 1995 Aug; 13(9):1079-86. PubMed ID: 8573631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: a 1H MRS study.
    Huang W; Alexander GE; Daly EM; Shetty HU; Krasuski JS; Rapoport SI; Schapiro MB
    Am J Psychiatry; 1999 Dec; 156(12):1879-86. PubMed ID: 10588400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of N-acetylator phenotype using caffeine as a probe compound: a comparison of high-performance liquid chromatography and capillary electrophoresis methods.
    Lloyd DK; Fried K; Wainer IW
    J Chromatogr; 1992 Jul; 578(2):283-91. PubMed ID: 1400808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease.
    Rumble B; Retallack R; Hilbich C; Simms G; Multhaup G; Martins R; Hockey A; Montgomery P; Beyreuther K; Masters CL
    N Engl J Med; 1989 Jun; 320(22):1446-52. PubMed ID: 2566117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered relationship between MMP-8 and TIMP-2 in gingival crevicular fluid in adolescents with Down's syndrome.
    Tsilingaridis G; Yucel-Lindberg T; Modéer T
    J Periodontal Res; 2013 Oct; 48(5):553-62. PubMed ID: 23298307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.